Brandon J. Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, . . . Nicolas Vanhoutte. (2024). Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Taylor & Francis Group.
Chicago Style (17th ed.) CitationBrandon J. Essink, et al. Safety and Immunogenicity of a Modified MRNA-lipid Nanoparticle Vaccine Candidate Against COVID-19: Results from a Phase 1, Dose-escalation Study. Taylor & Francis Group, 2024.
MLA (9th ed.) CitationBrandon J. Essink, et al. Safety and Immunogenicity of a Modified MRNA-lipid Nanoparticle Vaccine Candidate Against COVID-19: Results from a Phase 1, Dose-escalation Study. Taylor & Francis Group, 2024.
Warning: These citations may not always be 100% accurate.